TP Therapeutics Stock
TP Therapeutics is a structure-based drug design pharmaceutical company
Sign up today and learn more about TP Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About TP Therapeutics Stock
TP Therapeutics, Inc. is a structure-based drug design pharmaceutical company founded by Dr. J. Jean Cui, the lead inventor of Pfizer's Xalkori(TM) (generic name: crizotinib), the precision oncology drug for non-small cell lung cancer (NSCLC). Xalkori(TM) was approved by US Food and Drug Administration on August 26th, 2011.
Funding History
| January 2014 | $1.4M |
|---|---|
| March 2016 | $18.0M |
| May 2017 | $45.0M |
| October 2018 | $80.0M |
Management
Founder & CSO
J. Jean Cui
Senior Vice President, Clinical Operations and Regulatory Affairs
John K.C. Lim
CEO
Athena Countouriotis
Co-founder, Chairman, President, and CEO
Y. Peter Li
Vice President of Pre-Clinical Development
Jeffrey P. Whitten
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
